PARP inhibition in BRCA-mutated breast and ovarian cancers

Lancet. 2010 Jul 24;376(9737):211-3. doi: 10.1016/S0140-6736(10)61119-1.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics*
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Humans
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics*
  • Phthalazines / therapeutic use
  • Piperazines / therapeutic use
  • Poly(ADP-ribose) Polymerase Inhibitors*

Substances

  • Antineoplastic Agents
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • olaparib